Portfolio
Portfolio Companies Fund 2
Amakem
Sector: Ophthalmology
Country: Belgium
Amakem is using it’s Localized Drug Action platform for the development of kinase inhibitors. The primary focus is on eye disease.
Contacts
Dr. Gaston Matthyssens, Managing Partner Vesalius Biocapital III
Exact Imaging
Sector: Medical devices company
Country: Canada
Exact Imaging is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists will now be able to visualize areas of interest in the prostate and specifically target biopsies at those areas in addition to performing systematic biopsy protocols.
Contacts
Dr. Christian Schneider, Managing Partner Vesalius Biocapital III
Dr. Gaston Matthyssens, Managing Partner Vesalius Biocapital III
FF Pharmaceuticals
Sector: Antibody therapeutics
Country: The Netherlands / Belgium
FF Pharmaceuticals focuses on the development of novel disease-modifying therapeutics for the treatment of inflammatory diseases
Contacts
Stéphane Verdood, Managing Partner Vesalius Biocapital III
GenKyoTex
Sector: Therapeutics
Country: Switzerland / France
GenKyoTex is a product-driven biopharmaceutical company dedicated to the development of innovative therapeutics blocking the source of production of oxygen radicals in a specific manner to meet unmet medical need. Reverse Merger with Genticel, Euronext - quoted.
Contacts
Stéphane Verdood, Managing Partner Vesalius Biocapital III
Humedics
Sector: Diagnostic & prognostic assessment
Country: Germany
The goal of Humedics is to improve the diagnostic and prognostic assessment of severe liver diseases and to support doctors in improving and providing a more secure basis for their treatment decisions
Contacts
Dr. Christian Schneider, Managing Partner Vesalius Biocapital III
Ogeda - former Euroscreen
Sector: Drug Discovery and Development
Country: Belgium
New identity reflects Ogeda’s successful transition to GPCR drug discovery & development Ogeda develops drugs to validated GPCR targets in the areas of women’s health, inflammation and neurodegenerative diseases. Trade sale to Astellas in April 2017 for € 800 million.
Contacts
Alain Parthoens, Managing Partner Vesalius Biocapital III
Omeicos Therapeutics
Sector: Therapeutic
Country: Germany
Omeicos is developing novel small molecule drugs for the treatment and prevention of atrial fibrillation using a first-in-class novel metabolite of omega 3 fatty acids.
Contacts
Dr. Christian Schneider, Managing Partner Vesalius Biocapital III
Dr. Gaston Matthyssens, Managing Partner Vesalius Biocapital III
Pluriomics
Sector: Cell therapy
Country: Netherland
Pluriomics focusses on the development of fully functional human assay systems for use in drug discovery and development. Based on their novel proprietary methods for differentiation of stem cells, the company develops highly functional cell types like the Pluricyte Cardiomyocytes which are used in combination with phenotypic assays to deliver high quality results.
Contacts
Alain Parthoens, Managing Partner Vesalius Biocapital III
Softhale
Sector: Medical Devices
Country: Belgium
SOFTHALE is developing innovative drug/device products for the treatment mainly of asthma and COPD
Contacts
Dr. Christian Schneider, Managing Partner Vesalius Biocapital III
Trod Medical
Sector: Medical Devices & Tech
Country: France / Belgium / USA
The company develops Encage, a radio frequency ablation device for treating prostate cancer.
Contacts
Dr. Christian Schneider, Managing Partner Vesalius Biocapital III
Stéphane Verdood, Managing Partner Vesalius Biocapital III
Voluntis
Sector: Medical devices
Country: France
Voluntis develops state-of-the-art companion software to accompany and enhance a specific medical device or indication in the field of diabetes, coagulation and haemophilia.
Contacts
Alain Parthoens, Managing Partner Vesalius Biocapital III